Clinical Report: Infection Rates, Timing, and Predictive Factors in MM
Overview
Infections were observed in over half of newly diagnosed multiple myeloma patients, with a significant peak during the first three months of treatment. Key predictors of infection included advanced ISS stage, diabetes, and chronic kidney disease.
Background
Infections are a leading cause of morbidity and mortality in multiple myeloma (MM), particularly during the induction phase of treatment. Understanding infection trends and risk factors is crucial for developing effective preventive strategies. The high incidence of infections in this patient population underscores the need for targeted approaches to mitigate risks associated with immunosuppression.
Data Highlights
Outcome
Percentage
p-value
Infection Rate
50.9%
-
Peak Infection Rate (3 months)
27.3%
0.004
Pneumonia Incidence
34.1%
-
Key Findings
50.9% of patients experienced infections within the first 6 months.
Peak infection occurrence was noted at 27.3% during the initial 3 months (p = 0.004).
Pneumonia was the most common infection, accounting for 34.1% of cases.
Independent risk factors for infection included advanced ISS stage (OR: 3.83), diabetes mellitus (OR: 3.64), and chronic kidney disease (OR: 6.01).
Lymphocyte levels were significantly reduced during febrile episodes (p = 0.040).
No significant differences were found between induction treatment protocols regarding infection rates.
Clinical Implications
Clinicians should prioritize infection prevention strategies, particularly for patients with advanced ISS stage, diabetes, or chronic kidney disease. Early identification of high-risk patients can facilitate timely interventions to reduce infection-related morbidity during the induction phase of treatment.
Conclusion
Infections pose a significant challenge in the management of multiple myeloma, particularly in the early treatment phase. Implementing risk-adjusted strategies based on clinical indicators can enhance patient outcomes.
The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.
